Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$40.25 - $52.99 $21,453 - $28,243
533 Added 5.95%
9,494 $394,000
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $429,948 - $487,478
8,961 New
8,961 $485,000
Q2 2023

Jul 28, 2023

SELL
$63.71 - $70.74 $89,576 - $99,460
-1,406 Reduced 12.7%
9,661 $617,000
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $20,304 - $23,029
-309 Reduced 2.72%
11,067 $767,000
Q4 2022

Feb 07, 2023

BUY
$68.48 - $81.09 $30,062 - $35,598
439 Added 4.01%
11,376 $818,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $20 - $12,371
161 Added 1.49%
10,937 $778,000
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $93,897 - $103,414
1,293 Added 13.63%
10,776 $830,000
Q1 2022

Apr 27, 2022

BUY
$61.48 - $73.72 $377,056 - $452,124
6,133 Added 183.07%
9,483 $693,000
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $80,445 - $93,780
1,500 Added 81.08%
3,350 $209,000
Q2 2021

Aug 11, 2021

SELL
$61.91 - $67.42 $12,382 - $13,484
-200 Reduced 9.76%
1,850 $124,000
Q4 2020

Jan 27, 2021

SELL
$57.74 - $65.43 $17,610 - $19,956
-305 Reduced 12.95%
2,050 $127,000
Q3 2020

Oct 13, 2020

BUY
$57.43 - $63.64 $10,854 - $12,027
189 Added 8.73%
2,355 $142,000
Q2 2020

Jul 24, 2020

SELL
$54.82 - $64.09 $27,300 - $31,916
-498 Reduced 18.69%
2,166 $127,000
Q4 2019

Feb 05, 2020

BUY
$49.21 - $64.19 $787 - $1,027
16 Added 0.6%
2,664 $171,000
Q3 2019

Nov 06, 2019

SELL
$42.77 - $50.71 $1,668 - $1,977
-39 Reduced 1.45%
2,648 $134,000
Q1 2019

May 10, 2019

BUY
$45.12 - $53.8 $1,759 - $2,098
39 Added 1.47%
2,687 $128,000
Q4 2017

Feb 09, 2018

BUY
$59.94 - $65.35 $158,721 - $173,046
2,648
2,648 $162,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Crewe Advisors LLC Portfolio

Follow Crewe Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crewe Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Crewe Advisors LLC with notifications on news.